Tagged with Amgen

USA As part of our upcoming US Healthcare and Life Sciences Review, we spoke to key stakeholders – former Association for Accessible Medicines (AAM) president & CEO Chip Davis; Carol Lynch, president of Sandoz US, head of Sandoz North America and member of the Sandoz Executive Committee; and Amgen’s biosimilars business…

Amgen Alper Ureten, Amgen VP and General Manager, sits down with PharmaBoardroom to set out his ambitions and objectives for its Biosimilars Business Unit. Ureten also reveals the strategy behind their success with biosimilars and emphasises the need for competition and high quality to foster eco-system maturity.   The key priority…

France With Minister of the Economy and Finance, Bruno Le Maire, emphasizing the importance of “winning the battle on data” and eccentric mathematician Cédric Villani, well in the process of drawing up a national strategy on artificial intelligence (AI) in his capacity as Chargé de Mission, there is little doubting the…

Taiwan Joyce Lee, general manager of Amgen Taiwan, shares her journey of building up the affiliate after only having entered the market three years ago and goes on to offer insights on the island’s unique assets to the company’s operations.  Ms. Lee also highlights Amgen’s dedication to Taiwan’s healthcare system by…

Puerto Rico Rayne Waller, VP Manufacturing for Amgen Manufacturing Limited in Puerto Rico, is leading the operations at the company’s largest manufacturing facility in Juncos, which manufactures more than 90 percent of Amgen’s products. He highlights the importance and competitive advantages of Puerto Rico for Amgen, while also explaining why the company…

Puerto Rico With more than 50 years of experience in pharmaceutical manufacturing, Puerto Rico is today a manufacturing base for 11 of the world’s 20 largest pharmaceutical and biopharmaceutical companies. However, considering its economic struggles and rising competition both from US states and international manufacturing hubs such as Ireland and Singapore, the…

Egypt Ahmed Mostafa, country manager of Amgen in Egypt and Iran, explains how the affiliate has been growing by providing end-to-end solutions. He also gives his take on the Egyptian government’s prioritization of healthcare and highlights that there are still improvements needed for bringing biosimilars to Egypt.     How would…

France Jean Monin, general manager of Amgen France, discusses the challenges of bringing products to market in France and what is needed to better promote biosimilars. He also talks about his main achievements since joining the company six years ago.   We have been active in France for nearly 30 years…

UK Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of Amgen company culture.   Everyone tells you how complicated the UK market is and that is true – it’s one…

Algeria Radwa Terbeche, general manager of Amgen in Algeria discusses the potential for biosimilars in Algeria and the company’s role in developing a local clinical research infrastructure.   What has been your journey to becoming country manager of Amgen Algeria? By education I am a pharmacist specialized in industry. After graduating,…

UK Christine (Chris) Fox, VP and general manager UK and Ireland at Amgen, two months into her first country manager position and first time in a role outside of North America, discusses the creation of new, innovative partnership models with stakeholders across the healthcare spectrum, how Amgen is leveraging its biologic…

Pharma What is VR and why should healthcare and pharmaceutical companies take note? VR (Virtual Reality) places the user into a virtual world. VR differs from Augmented Reality (AR), which sets virtual objects against the backdrop of the real world—as in Pokemon Go, the augmented reality smartphone craze of 2016—or simply…